BioTime’s Subsidiary OncoCyte Corporation Provides An Update On The Development Of The Novel Pan-Cancer Diagnostic Product PanC-DxTM
BioTime, Inc. (NYSE MKT: BTX) and BioTime’s subsidiary OncoCyte
Corporation provided an update on the progress of development of
a novel blood-based diagnostic test utilizing molecular markers
Investors considering a purchase of BioTime, Inc. shares, but tentative about paying the going market price of $3.26/share, might benefit from considering selling puts among the alternative strategies at their disposal.